Keenova Therapeutics plc: Nasdaq/NYSE listing notice — Mallinckrodt receives NYSE American delisting notice after Chapter 11 filing; shares cancelled for no consideration

Keenova Therapeutics plc

NYSE American notified Mallinckrodt on Aug 28, 2023 of immediate trading suspension and delisting proceedings.
Delisting triggered by Company's voluntary Chapter 11 filing on Aug 28, 2023 in U.S. Bankruptcy Court for Delaware.
Restructuring Support Agreement (Aug 23, 2023) provides for cancellation of all ordinary shares for no consideration.
Company's ordinary shares (MNK) will be suspended immediately from NYSE American.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Keenova Therapeutics plc received a nyse_american delisting notice notice regarding other (rules 1003(c)(iii)).

Exchange: nyse american
Notice: delisting notice
Rules: 1003(c)(iii)

Exact text from the filing

August 28, 2023, Mallinckrodt plc (the “Company”) was notified by the staff of NYSE Regulation that NYSE Regulation has determined to commence proceedings to delist the ordinary shares, par value $0.01 per share, of the Company from the NYSE American LLC (“NYSE American”) and that trading in the Company’s ordinary shares will be suspended immediately. NYSE Regulation advised that it has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c)(iii) of the NYSE American Company Guide in light of the Company’s disclosure on

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-096203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.